Overview

1. CHLA IRB review fees are applied to the following types of studies:
   - Ongoing single site and multi-site industry sponsored studies that are reviewed by the CHLA IRB.
   - New investigator initiated, single site or multi-site industry sponsored studies that are reviewed by the CHLA IRB.
   - New industry initiated and sponsored, multi-center clinical trials that have not been reviewed by a central IRB.

2. Investigators may use the central IRB chosen by the study Sponsor for new industry initiated and sponsored, multi-center clinical trials. Most studies are reviewed by the WCG IRB or Advarra IRB.
   - IRB review fees should be billed directly to the Sponsor when WCG IRB or Advarra IRB, or another commercial IRB is the central IRB for the study.

3. There are no IRB review fees for ceded review submissions, regardless of the source of funding.

4. There are no IRB review fees for federally funded research.

5. There are no IRB review fees for research supported by departmental funds, foundation grant/contract, intramural/internal grant, residual funds, state or local grant/contract, and studies that involve no funding.

CHLA IRB Review Fees

CHLA IRB review fees are as follows:

- Initial Reviews: $2,500
- Continuing Reviews: $500
- Full Board Amendments: $500
- Closure Reports: $500